Autolus Stock Jumps On Cancer mRNA Therapeutics Agreement With Moderna

Autolus Stock Jumps On Cancer mRNA Therapeutics Agreement With Moderna
  • Autolus Therapeutics plc AUTL has granted Moderna Inc MRNA an exclusive license to develop and commercialize mRNA therapeutics incorporating Autolus' proprietary binders for up to four immuno-oncology targets.
  • Autolus would be eligible to receive an upfront payment for each target licensed by Moderna and milestone payments. 
  • In addition, Autolus would be entitled to receive royalties on net sales.
  • Price Action: AUTL shares are up 16.9% at $6.22, while MRNA stock is +2.1% at $360.95 during the premarket session on the last check Monday.

Posted In: BriefscancermRNA vaccinesBiotechNewsHealth CareContractsSmall CapGeneral